Otis W. Brawley - Jun 16, 2022 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role: Director
Signature: /s/ Charles Newton, as Attorney-in-Fact
Stock symbol: LYEL
Transactions as of: Jun 16, 2022
Transactions value $: $0
Form type: 4
Date filed: 6/20/2023, 04:41 PM
Previous filing: Jun 17, 2022
Next filing: Jun 29, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LYEL	Option (right to buy)	Award	$0	+65K		$0.00	65K	Jun 16, 2023	Common Stock	65K	$3.19	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 16, 2023 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 16, 2023, subject to the Reporting Person providing continuous service through such date.

Content

The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 16, 2023 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 16, 2023, subject to the Reporting Person providing continuous service through such date.